Penserra Capital Management
ATRA icon

Penserra Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Penserra Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-78
Closed -$34K – 1377
2021
Q3 		$34K Buy
78
+1
+1% +$358 ﹤0.01% 1154
2021
Q2 		$29K Buy
77
+2
+3% +$713 ﹤0.01% 1097
2021
Q1 		$26K Buy
75
+4
+6% +$1.77K ﹤0.01% 924
2020
Q4 		$35K Buy
71
+46
+184% +$21.2K ﹤0.01% 746
2020
Q3 		$8K Buy
+25
New +$8.51K ﹤0.01% 831

Other funds holding ATRA

Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Maverick Capital
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Penserra Capital Management's ATRA Position: Q4 2021 in Review

Penserra Capital Management sold out of Atara Biotherapeutics (ATRA) in Q4 2021, closing a stake of 78 shares — an estimated $34K sold.

Penserra Capital Management first reported a position in ATRA in Q3 2020 and held it in 5 quarters. The position peaked at $35K in Q4 2020. 139 funds tracked by Wall St. Rank hold ATRA as of Q4 2021.

  • Penserra Capital Management reported no remaining Atara Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 78 Atara Biotherapeutics shares in Q4 2021, an estimated $34K.
  • Penserra Capital Management first reported a position in Atara Biotherapeutics in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Atara Biotherapeutics position peaked at $35K in Q4 2020.
  • 139 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.